For the Inventor, By the Inventor

Enter assignee name

Watertown, MA, United States of America

C4 Therapeutics, Inc.

USPTO Granted Patents = 40

EPO Patents = 6

Trademarks = 8

Forward Citations = 221

Loading Chart...

Loading Chart...

58 inventors (with patents filed for the assignee):

Christopher G Nasveschuk (28 out of 66 patents)

James A Henderson (20 out of 29 patents)

Yanke Liang (20 out of 42 patents)

4. Andrew John Phillips (19 out of 49 patents)

5. Minsheng He (17 out of 29 patents)

6. Kiel Lazarski (13 out of 26 patents)

7. Annick Goergler (11 out of 27 patents)

8. Fabian Dey (10 out of 28 patents)

9. Gesine Kerstin Veits (10 out of 11 patents)

10. Roger David Norcross (10 out of 94 patents)

11. Ryan E Michael (9 out of 9 patents)

12. Martin Duplessis (9 out of 29 patents)

13. Eric Andre Kusznir (7 out of 7 patents)

14. Katrina L Jackson (7 out of 7 patents)

15. Mark E Fitzgerald (6 out of 6 patents)

40 patents: Sort by Forward Citations

1. 12746238 - Selected compounds for targeted degradation of BRD9 (2026-09-29),

2. 12729193 - TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 (2026-09-08),

3. 12721852 - Advantageous therapies for disorders mediated by Ikaros or Aiolos (2026-09-01),

4. 12662488 - Spirocyclic compounds (2026-06-23),

5. 12605450 - C3-carbon linked glutarimide Degronimers for target protein degradation (2026-04-21),

6. 12570626 - Degraders and degrons for targeted protein degradation (2026-03-10),

7. 12559492 - BRAF degraders (2026-02-24),

8. 12528797 - Heterocyclic compounds for medical treatment (2026-01-20),

9. 12486290 - Isoindolinone and indazole compounds for the degradation of EGFR (2025-12-02),

10. 12486253 - Therapeutics for the degradation of mutant BRAF (2025-12-02),

11. 12454521 - Targeted protein degradation (2025-10-28),

12. 12441740 - N/O-linked degrons and degronimers for protein degradation (2025-10-14),

13. 12421220 - Bicyclic-substituted glutarimide cereblon binders (2025-09-23),

14. 12371442 - Isoindolinone and indazole compounds for the degradation of EGFR (2025-07-29),

15. 12365681 - Dihydrobenzimidazolones for medical treatment (2025-07-22),

C4 Therapeutics, Inc. is a biotechnology company focused on developing targeted protein degradation therapeutics. Their approach uses small molecules to tag proteins for degradation, offering potential treatments for a broad range of diseases, including cancer and neurodegenerative disorders.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

40 Patents

#14 in Watertown, MA

#496 in Massachusetts

#8,612 in US

#17,031 in the World

Watertown, MA, United States of America

C4 Therapeutics, Inc.

Forward Citations = 221

58 inventors:

Christopher G Nasveschuk (28 out of 66 patents)

James A Henderson (20 out of 29 patents)

Yanke Liang (20 out of 42 patents)

4. Andrew John Phillips (19 out of 49 patents)

5. Minsheng He (17 out of 29 patents)

Please report any incorrect information to [email protected]

Loading…